200 related articles for article (PubMed ID: 24252009)
1. Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome - Successful use of PET- CT and Anakinra in its diagnosis and treatment.
Tayer-Shifman OE; Ben-Chetrit E
Mod Rheumatol; 2015; 25(6):954-7. PubMed ID: 24252009
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra.
Loh NK; Lucas M; Fernandez S; Prentice D
Intern Med J; 2012 Dec; 42(12):1358-62. PubMed ID: 23253002
[TBL] [Abstract][Full Text] [Related]
3. Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.
Aytaç S; Batu ED; Ünal Ş; Bilginer Y; Çetin M; Tuncer M; Gümrük F; Özen S
Rheumatol Int; 2016 Oct; 36(10):1421-9. PubMed ID: 27510530
[TBL] [Abstract][Full Text] [Related]
4. Acute respiratory distress syndrome associated with macrophage activation syndrome in systemic lupus erythematosus: A case report and literature review.
Chang ES; Yu HH; Wu CE; Chan TM
Medicine (Baltimore); 2022 Feb; 101(5):e28612. PubMed ID: 35119005
[TBL] [Abstract][Full Text] [Related]
5. Macrophage activation syndrome triggered by active systemic lupus erythematosus : Successful treatment by interleukin-1 inhibition (anakinra).
Kübler L; Bittmann I; Kuipers JG
Z Rheumatol; 2020 Dec; 79(10):1040-1045. PubMed ID: 32804304
[TBL] [Abstract][Full Text] [Related]
6. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
7. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome.
Kahn PJ; Cron RQ
J Rheumatol; 2013 May; 40(5):743-4. PubMed ID: 23637382
[No Abstract] [Full Text] [Related]
8. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults.
Kumar B; Aleem S; Saleh H; Petts J; Ballas ZK
J Clin Immunol; 2017 Oct; 37(7):638-643. PubMed ID: 28871523
[TBL] [Abstract][Full Text] [Related]
9. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: A case report treated with high doses (8 mg/kg/d) of anakinra.
Parisi F; Paglionico A; Varriano V; Ferraccioli G; Gremese E
Medicine (Baltimore); 2017 Jun; 96(24):e6656. PubMed ID: 28614216
[TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristics of macrophage activation syndrome secondary to systemic lupus erythematosus].
Jiang N; Li MT; Wu D; Zeng XF
Zhonghua Nei Ke Za Zhi; 2016 Nov; 55(11):840-844. PubMed ID: 27801337
[No Abstract] [Full Text] [Related]
11. Macrophage activation syndrome treated with anakinra.
Durand M; Troyanov Y; Laflamme P; Gregoire G
J Rheumatol; 2010 Apr; 37(4):879-80. PubMed ID: 20360206
[No Abstract] [Full Text] [Related]
12. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients.
Wafa A; Hicham H; Naoufal R; Hajar K; Rachid R; Souad B; Mouna M; Zoubida MT; Mohamed A
Clin Rheumatol; 2022 Jul; 41(7):2021-2033. PubMed ID: 35179662
[TBL] [Abstract][Full Text] [Related]
13. Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
Junga Z; Stitt R; Tracy C; Keith M
BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28827301
[TBL] [Abstract][Full Text] [Related]
14. A case of macrophage activation syndrome successfully treated with anakinra.
Kelly A; Ramanan AV
Nat Clin Pract Rheumatol; 2008 Nov; 4(11):615-20. PubMed ID: 18825135
[TBL] [Abstract][Full Text] [Related]
15. Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China.
Liu AC; Yang Y; Li MT; Jia Y; Chen S; Ye S; Zeng XZ; Wang Z; Zhao JX; Liu XY; Zhu J; Zhao Y; Zeng XF; Li ZG
Clin Rheumatol; 2018 Jan; 37(1):93-100. PubMed ID: 28409239
[TBL] [Abstract][Full Text] [Related]
16. Macrophage activation syndrome resistant to medical therapy in a patient with systemic lupus erythematosus and its remission with splenectomy.
Kim JM; Kwok SK; Ju JH; Park KS; Park GS; Kim HY; Park SH
Rheumatol Int; 2013 Mar; 33(3):767-71. PubMed ID: 21120496
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of anakinra in children with macrophage activation syndrome.
Phadke O; Rouster-Stevens K; Giannopoulos H; Chandrakasan S; Prahalad S
Pediatr Rheumatol Online J; 2021 Jun; 19(1):98. PubMed ID: 34187503
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
[TBL] [Abstract][Full Text] [Related]
19. In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome.
Ahn SS; Yoo BW; Jung SM; Lee SW; Park YB; Song JJ
Semin Arthritis Rheum; 2017 Oct; 47(2):216-221. PubMed ID: 28268026
[TBL] [Abstract][Full Text] [Related]
20. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.
Sönmez HE; Demir S; Bilginer Y; Özen S
Clin Rheumatol; 2018 Dec; 37(12):3329-3335. PubMed ID: 29663156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
